World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 11 May 2020
Main ID:  EUCTR2019-000374-39-GB
Date of registration: 09/05/2019
Prospective Registration: Yes
Primary sponsor: Orphazyme A/S
Public title: Extension study of Arimoclomol in patients with amyotrophic lateral sclerosis.
Scientific title: Open-label, Non-randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS) who have Completed the ORARIALS-01 Trial
Date of first enrolment: 15/07/2019
Target sample size: 231
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000374-39
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Canada Denmark France Germany Italy Netherlands Poland
Spain Sweden Switzerland United Kingdom United States
Contacts
Name: Senior Clinical Trial Manager   
Address:  Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark
Telephone: 0045 31391062
Email: hda@orphazyme.com
Affiliation:  Orphazyme A/S
Name: Senior Clinical Trial Manager   
Address:  Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark
Telephone: 0045 31391062
Email: hda@orphazyme.com
Affiliation:  Orphazyme A/S
Key inclusion & exclusion criteria
Inclusion criteria:
1. Subject is able to comprehend and is willing to provide written informed consent and is capable and willing to comply with trial procedures or in the circumstance that the subject is incompetent, informed consent/assent is provided in accordance with local regulation and/or procedures.
2. Subject has completed the ORARIALS-01 trial (i.e., met one of the surrogate survival endpoints of tracheostomy or PAV or has completed the 76 weeks randomised treatment period).
3. Subject completed ORARIALS-01 while on treatment, where on treatment is defined as having taken the last dose of IMP within 2 weeks of the End of Trial visit. (whether at week 76 or prior).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 160
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 71

Exclusion criteria:
1. Known or suspected allergy or intolerance to the IMP (arimoclomol or constituents).
2. Exposure to any other investigational treatment, advanced therapy medicinal product(ATMP) or use of any other prohibited concomitant medications.
3. Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of birth control if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants until 3 months after last dose. Pre-menopausal women must have a negative pregnancy test prior to dosing with trial medication. Acceptable methods of birth control are:
a. Hormonal methods associated with inhibition of ovulation such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject’s usual menstrual cycle period) before IMP administration.
b. Total abstinence from sexual intercourse since the last menses before IMP administration. (The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence methods [calendar, symptothermal, post-ovulation methods] are not acceptable methods of contraception).
c. Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
4. Any of the following medically significant conditions:
a. Clinically significant renal or hepatic disease OR clinical laboratory assessment (results = 3 times the upper limit of normal [ULN] for aspartate aminotransferase, and/or alanine aminotransferase, bilirubin = 2 times the ULN, or creatinine = 1.5 times the ULN).
b. Any new condition or worsening of existing condition which, in the opinion of the investigator would put the subject at undue risk.
5. Any serious adverse event or moderate/severe adverse event from the ORARIALS-01 trial which is ongoing at the time of transitioning to ORARIALS-02 and assessed as probably related to IMP.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Amyotrophic Lateral Sclerosis
MedDRA version: 21.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders
Intervention(s)

Product Name: Arimoclomol
Product Code: BRX-345
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: ARIMOCLOMOL
CAS Number: 368860-21-3
Current Sponsor code: BRX-345
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-

Primary Outcome(s)
Secondary Objective: To evaluate the long-term efficacy of arimoclomol treatment of ALS.
Main Objective: To assess the long-term safety of arimoclomol treatment of ALS.
Timepoint(s) of evaluation of this end point: 76 weeks (or end-of-trial)
Primary end point(s): 1. Incidence and severity of TEAEs over a treatment period of 76 weeks
2. Mean and change from Baseline (of the present trial) to Week 76 (or end of trial) in clinical safety laboratory tests and vital signs
3. Incidence of potentially clinically significant abnormalities in clinical safety laboratory tests and vital signs over a treatment period of 76 weeks
4. C-SSRS over a treatment period of 76 weeks
Secondary Outcome(s)
Secondary end point(s): 1. Time to PAV/tracheostomy/death (for subjects entering this trial having completed 76 weeks of randomised treatment in ORARIALS-01)
2. Change in ALSFRS-R from Baseline (of the present trial) to the end of the trial
3. Change in SVC from Baseline (of the present trial) to the end of the trial (for subjects who did not meet the survival endpoint in the ORARIALS-01 trial)
Timepoint(s) of evaluation of this end point: 76 weeks (or end-of-trial)
Secondary ID(s)
ORARIALS-02
NCT03836716
Source(s) of Monetary Support
Orphazyme A/S
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 15/07/2019
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey